mynth
← DATABASE
04/2026

THERMO FISHER MICROBIOLOGY acquired by ASTORG

UNITED STATES Life Sciences / Medical Devices / Diagnostic Equipment EV 1b - 4b USD

Context

Astorg has signed a definitive agreement to acquire Thermo Fisher Scientific's microbiology business, which will become an independent, privately owned platform, backed by Astorg. The transaction consists of a complete corporate carve-out, executed via the Astorg VIII fund, representing the vehicle's tenth investment to date and further concentrating its portfolio exposure within the life sciences sector. The ownership transition is driven by the seller’s strategic decision to divest non-core clinical assets, allowing the parent company to reallocate its corporate capital toward higher-growth molecular diagnostics. For the target company, the separation from a large corporate matrix removes internal budget competition and enables dedicated reinvestment into product innovation. The ownership transition establishes a clear operational mandate focused on scaling global market share, expanding the current commercial infrastructure, and pursuing consolidation via strategic mergers and acquisitions. The post-closing roadmap requires the execution of complex transitional service agreements to ensure continuity across thirteen global manufacturing and research facilities without disrupting ongoing supply contracts. The definitive agreement is subject to customary anti-trust clearances and regulatory approvals, with final closing projected during the second half of 2026.

THERMO FISHER MICROBIOLOGY, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

The microbiology division of Thermo Fisher Scientific, commercialized globally under the legacy Remel and Oxoid brands, operates as a developer and manufacturer of diagnostic consumables and equipment utilized in clinical, pharmaceutical, and food safety testing laboratories. The entity focuses on specialized culture media solutions and automated antimicrobial susceptibility testing systems designed for pathogen identification. These physical products represent critical operational components within specialized testing workflows where chemical exactness determines clinical outcomes. Revenue generation is driven by the regular replenishment of single-use testing consumables, which accounts for over 95% of total turnover across thirty-eight thousand active laboratories. This transacting mechanism benefits from deep institutional inertia as laboratories anchor their standardized daily testing protocols to the specific chemical profiles of these brands. Switching to alternative vendors requires extensive internal validation protocols and regulatory re-certification of testing lines, creating high friction and substantial financial switching barriers. Furthermore, the operational landscape is governed by increasingly rigid international public health mandates and pharmaceutical quality control laws. These strict baseline requirements compel testing facilities to rely exclusively on audited, established market suppliers, neutralizing commodity-grade competition.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (USD)

Year
Rev
EBITDA
EBIT
2025
LOGIN
LOGIN
LOGIN
2024
LOGIN
LOGIN
LOGIN

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
DateAcquirerTargetCountrySectorDeal Context
06/2026BRIDGEPOINTOBAGI MEDICALUNITED STATESLife Sciences

Obagi Medical, a medical-grade skincare company positioned in the professional dermatology and aesthetics segment, is being acquired by Bridgepoint as part of a broader consolidation trend across clinical skincare markets

05/2026STRYKERAMPLITUDE VASCULAR SYSTEMSUNITED STATESLife Sciences

Stryker has completed the acquisition of Amplitude Vascular Systems, a private medical device company, which develops a next-generation intravascular lithotripsy (IVL) platform, designed to treat complex peripheral arterial disease, this acquisition represents a significant milestone in the expansion of Stryker's peripheral vascular portfolio, by integrating Amplitude Vascular Systems' innovative technology, which uses carbon dioxide-generated pressure waves, to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with the goal of strengthening Stryker's position in peripheral vascular solutions, by offering solutions for physicians and patients, to treat cardiovascular disease, Stryker's strategy is to develop its portfolio of products and services, to improve patient and healthcare outcomes, by offering innovative and integrated solutions, for physicians, hospitals, and patients, financial and legal advisory services were provided by reputable consulting firms, to ensure the success of the operation

04/2026UCBNEURONA THERAPEUTICSUNITED STATESLife Sciences

UCB has entered into a definitive agreement to acquire Neurona Therapeutics, a maneuver designed to fundamentally reinforce the group’s leadership in the global epilepsy market. The strategic rationale for this transaction centers on a "regeneration-acceleration" play, merging the target's industry-leading stem cell platform with the group’s extensive therapeutic expertise and global commercial infrastructure

04/2026DEVYSER DIAGNOSTICSCYBERGENESWEDENLife Sciences

Devyser Diagnostics AB has finalized the acquisition of CyberGene AB from Level Bio AB. The strategic rationale for this transaction centers on a "portfolio-optimization" play, merging the target's established diagnostic kits in aneuploidy and infertility with the group's global commercial infrastructure and direct sales force

04/2026VITREX MEDICAL GROUPHERNIAMESHITALYLife Sciences

Vitrex Medical Group (VMG) has finalized the acquisition of a majority stake in Herniamesh, an operation designed to fundamentally accelerate the group's transformation into a global leader in surgical technology

04/2026OURY MEDICALCÉFIMÉCAFRANCELife Sciences

The acquisition of Céfiméca by Oury Medical represents a strategic consolidation within the French orthopedic and spinal medical device market. This transaction is the fifth build-up operation completed by Oury Medical in three years, following a platform strategy initiated by its lead investors

04/2026RANTUM CAPITALTONTARRA MEDIZINTECHNIKGERMANYLife Sciences

Rantum Private Equity Fund II has successfully finalized the acquisition of a majority stake in the share capital of the target, marking its seventh investment from the current fund. This strategic transaction represents a pivotal step in the acquirer’s objective to establish a dominant position in the high-precision medical technology sector, specifically targeting the resilient demand for minimally invasive surgery

04/2026REVENIO GROUP CORPORATIONVISIONIX INTERNATIONALFRANCELife Sciences

The group has finalized a definitive agreement to acquire the entire share capital of the target, a maneuver designed to fundamentally expand its presence as a turnkey provider in the global eye care market

04/2026AMERICAN INDUSTRIAL PARTNERS AIPAVANOS MEDICALUNITED STATESLife Sciences

American Industrial Partners has finalized a definitive agreement to acquire Avanos Medical in an all-cash transaction, a maneuver designed to fundamentally reinforce the target's competitive positioning in the specialized medical technology arena

04/2026FOR TALENTS / UI INVESTISSEMENT / GENEONEFTYS PHARMAFRANCELife Sciences

In a structured minority growth equity transaction, specialized family capital investment firm For Talents has acquired a minority stake in Neftys Pharma. This strategic operation is executed alongside incumbent financial sponsors UI Investissement and GENEO Capital Entrepreneur, who are rolling over their investments after an initial four-year holding period

REFERENCES

Valuation range: EV 1b - 4b USD

Revenue range: 450M - 900M USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of THERMO FISHER MICROBIOLOGY by ASTORG are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: astorg